Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
GHSI - Guardion Health Sciences, Inc.
Market Cap 9.38M P/E - EPS this Y - Ern Qtrly Grth -
Income -5.28M Forward P/E -3.12 EPS next Y - 50D Avg Chg 4.00%
Sales 12.23M PEG - EPS past 5Y - 200D Avg Chg 5.00%
Dividend N/A Price/Book 1.11 EPS next 5Y - 52W High Chg -30.00%
Recommedations 2.00 Quick Ratio 16.17 Shares Outstanding 1.28M 52W Low Chg 59.00%
Insider Own 1.36% ROA -15.53% Shares Float 1.15M Beta 0.74
Inst Own 21.52% ROE -50.26% Shares Shorted/Prior 47.83K/55.59K Price 7.40
Gross Margin 44.56% Profit Margin 52.13% Avg. Volume 9,553 Target Price -
Oper. Margin -1,875.34% Earnings Date Nov 11 Volume 2,180 Change -2.63%
Healthcare | Drug Manufacturers - Specialty & Generic | United States
About Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Guardion Health Sciences, Inc. News
12/23/24 Guardion Health Sciences Announces Declaration of Cash Distribution
10/30/24 Guardion Health Sciences Announces Filing of Certificate of Dissolution
10/04/24 Guardion Health Sciences Announces Delisting and New Interim CEO
10/01/24 Guardion Health Sciences Announces Adoption of Plan of Dissolution and Liquidation; Appointment of Interim President and CEO
08/21/24 Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock
08/16/24 Guardion Health Sciences Second Quarter 2024 Earnings: US$1.66 loss per share (vs US$0.93 loss in 2Q 2023)
08/13/24 Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024
05/31/24 Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor’s Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution
05/23/24 Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business
05/21/24 Guardion Health Sciences Announces its Largest Stockholder Has Voted in Favor of Proposals to Sell the Viactiv Business and the Liquidation Plan at the Company’s Special Meeting of Stockholders to be held on May 23, 2024
05/13/24 Guardion Health Sciences Announces
04/01/24 Why Guardion Health Sciences, Inc. (NASDAQ:GHSI) Could Be Worth Watching
03/29/24 Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023
01/30/24 Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor’s Best Inc.
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Radoff Bradley Louis 10% Owner 10% Owner Jan 09 Buy 7.32 116,721 854,398 217,900 01/11/23